Precision Competitors
| DTIL Stock | USD 4.07 0.31 8.24% |
Precision BioSciences vs Quince Therapeutics Correlation
Average diversification
The correlation between Precision BioSciences and QNCX is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Precision BioSciences and QNCX in the same portfolio, assuming nothing else is changed.
Moving together with Precision Stock
Moving against Precision Stock
| 0.83 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.78 | DSGN | Design Therapeutics | PairCorr |
| 0.64 | ENGN | enGene Holdings Common | PairCorr |
| 0.57 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.51 | KYTX | Kyverna Therapeutics | PairCorr |
Precision BioSciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Precision BioSciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Precision and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Precision BioSciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Precision Stock performing well and Precision BioSciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Precision BioSciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MGX | 3.04 | (0.70) | 0.00 | (0.23) | 0.00 | 6.21 | 18.63 | |||
| ALXO | 5.65 | 1.43 | 0.23 | (1.55) | 5.17 | 13.11 | 27.69 | |||
| ADVM | 3.39 | 0.39 | 0.09 | 0.63 | 3.70 | 10.34 | 40.97 | |||
| ARTV | 6.44 | 0.64 | 0.09 | 0.50 | 7.28 | 8.00 | 118.69 | |||
| STRO | 4.95 | 0.85 | 0.14 | 0.72 | 5.23 | 11.87 | 29.10 | |||
| GUTS | 5.13 | (0.62) | 0.00 | (0.85) | 0.00 | 11.89 | 85.71 | |||
| RPTX | 2.16 | 0.54 | 0.22 | 1.64 | 1.47 | 3.95 | 35.71 | |||
| ATYR | 4.05 | 0.34 | 0.08 | 0.44 | 3.78 | 10.23 | 35.20 | |||
| CNTB | 4.71 | 1.07 | 0.17 | (0.58) | 4.38 | 11.93 | 38.27 | |||
| QNCX | 13.02 | 3.71 | 0.20 | 2.57 | 15.64 | 16.82 | 120.72 |
Cross Equities Net Income Analysis
Compare Precision BioSciences and related stocks such as Metagenomi Common Stock, Alx Oncology Holdings, and Adverum Biotechnologies Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGX | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (43.6 M) | (68.3 M) | (78.1 M) | (78.1 M) | (70.3 M) | (73.8 M) |
| ALXO | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (19.2 M) | (45.7 M) | (83.5 M) | (123.5 M) | (160.8 M) | (134.8 M) | (121.4 M) | (127.4 M) |
| ARTV | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (71.8 M) | (58.4 M) | (27.7 M) | (58.5 M) | (52.6 M) | (55.3 M) |
| STRO | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | (19.7 M) | (35.3 M) | (55.7 M) | (32.1 M) | (105.5 M) | (119.2 M) | (106.8 M) | (227.5 M) | (204.7 M) | (194.5 M) |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| ATYR | (17.6 M) | (17.6 M) | (17.6 M) | (20 M) | (24.4 M) | (48 M) | (57.9 M) | (48.2 M) | (34.5 M) | (23.6 M) | (16.2 M) | (33.8 M) | (45.3 M) | (50.4 M) | (64 M) | (57.6 M) | (60.5 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| QNCX | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.5 M) | (37 M) | (76.8 M) | (89.9 M) | (51.7 M) | (31.4 M) | (56.8 M) | (51.1 M) | (53.7 M) |
Precision BioSciences and related stocks such as Metagenomi Common Stock, Alx Oncology Holdings, and Adverum Biotechnologies Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Precision BioSciences financial statement analysis. It represents the amount of money remaining after all of Precision BioSciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Precision BioSciences Competitive Analysis
The better you understand Precision BioSciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Precision BioSciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Precision BioSciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Precision BioSciences Competition Performance Charts
Five steps to successful analysis of Precision BioSciences Competition
Precision BioSciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Precision BioSciences in relation to its competition. Precision BioSciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Precision BioSciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Precision BioSciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Precision BioSciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Precision BioSciences position
In addition to having Precision BioSciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 335 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Precision BioSciences Correlation with its peers. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.96) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.